TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05594069

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: triple pre-rehabilitation
Description: The triple intervention consisted of exercise, nutrition and psychology. Based on the intervention framework, face-to-face intervention adjustment and intensive intervention measures were carried out from the time of enrollment (T0). Combined with weekly telephone follow-up during the intervention, the intervention content formulated face-to-face last time was reviewed, reinforcement behaviors were performed, and questions were answered during the intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: triple rehabilitation
Description: The triple intervention consisted of exercise, nutrition and psychology. Based on the intervention framework, face-to-face intervention adjustment and intensive intervention measures were carried out at the time of the beginning of radiotherapy (T1), and the middle stage of radiotherapy (T2). Combined with weekly telephone follow-up during the intervention, the intervention content formulated face-to-face last time was reviewed, reinforcement behaviors were performed, and questions were answered during the intervention.

Intervention type: OTHER
Group type: OTHER
Intervention: triple rehabilitation
Description: The triple intervention consisted of exercise, nutrition and psychology. Based on the intervention framework, face-to-face intervention adjustment and intensive intervention measures were carried out at the time of the beginning of radiotherapy (T1), and the middle stage of radiotherapy (T2). Combined with weekly telephone follow-up during the intervention, the intervention content formulated face-to-face last time was reviewed, reinforcement behaviors were performed, and questions were answered during the intervention.
Study: NCT04585711

Intervention type: DRUG
Group type: OTHER
Intervention: Etanercept Optimal dosing
Description: Patients will receive Etanercept on an optimal dose interval over a 6-week period based on a PK/PD model.
Study: NCT04774900

Intervention type: PROCEDURE
Intervention: Administration of oxygen
Description: Administration of high-flow oxygen via face mask to a high fidelity mannequin.

Intervention type: PROCEDURE
Intervention: Administration of oxygen
Description: Administration of high-flow oxygen via face mask to a high fidelity mannequin.

Intervention type: PROCEDURE
Intervention: Administration of drug in a nebulizer
Description: Administration of bronchodilator via nebulizer mask to a high fidelity mannequin.

Intervention type: PROCEDURE
Intervention: Administration of drug in a nebulizer
Description: Administration of bronchodilator via nebulizer mask to a high fidelity mannequin.

Intervention type: PROCEDURE
Intervention: Securing intravenous line
Description: Securing an intravenous line at the forearm of high fidelity mannequin.

Intervention type: PROCEDURE
Intervention: Securing intravenous line
Description: Securing an intravenous line at the forearm of high fidelity mannequin.

Intervention type: PROCEDURE
Intervention: Administration of IV drug
Description: Administration of bronchodilator via IV line to a high fidelity mannequin.

Intervention type: PROCEDURE
Intervention: Administration of IV drug
Description: Administration of bronchodilator via IV line to a high fidelity mannequin.

Intervention type: PROCEDURE
Intervention: Needle decompression of tension pneumothorax
Description: Needle decompression of tension pneumothorax on a high fidelity mannequin.

Intervention type: PROCEDURE
Intervention: Needle decompression of tension pneumothorax
Description: Needle decompression of tension pneumothorax on a high fidelity mannequin.
Study: NCT05420220

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KN046 (Recombinant Humanized PD-L1/CTLA-4 Bispecific Single Domain Antibody Fc Fusion Protein Injection)
Description: 5 mg/kg Q3W IV

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: 5mg bid po
Study: NCT05059223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXS-12 (reboxetine)
Description: AXS-12 tablets, taken twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets, taken twice daily
Study: NCT05777122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lignocaine gel
Description: pharmacological ,topical anesthetic gel

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sugar free chewing gum
Description: non pharmacological
Study: NCT05743075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensifentrine
Description: A dual PDE3/PDE 4 inhibitor
Study: NCT06218355

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Education
Description: Intervention will consist of virtual education and communication through scheduled push notifications

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Virtual Care
Description: Intervention will utilize a telehealth model consisting of pull approach of patient engagement.
Study: NCT04658095

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OMNI® Surgical System
Description: Ab-interno canaloplasty (360 degrees) and up to 360 degrees trabeculotomy using the OMNI Surgical System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iStent inject
Description: Ab-interno implantation of iStent inject (2 microstents)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OMNI® Surgical System
Description: Ab-interno canaloplasty (360 degrees) using the OMNI Surgical System
Study: NCT05497674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rongliflozin
Description: oral administration, single dose on Day 1 and Day 11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: QD for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rongliflozin
Description: oral administration, single dose on Day 1 and Day 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probenecid
Description: twice a day, for 5 days
Study: NCT05743075

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution
Study: NCT06224660

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SRD-001
Description: SRD-001 is an adeno-associated virus serotype 1 (AAV1) based gene therapy designed to deliver a copy of the gene encoding the human sarcoplasmic/endoplasmic reticulum Ca(2+) ATPase 2a (SERCA2a). It is administered as a one-time intracoronary infusion.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SRD-001
Description: SRD-001 is an adeno-associated virus serotype 1 (AAV1) based gene therapy designed to deliver a copy of the gene encoding the human sarcoplasmic/endoplasmic reticulum Ca(2+) ATPase 2a (SERCA2a). It is administered as a one-time intracoronary infusion.
Study: NCT06459843

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pursed lip breathing techniques
Description: Relax your neck and shoulder muscles. For the use of PLB exercise, the intervention will be given every day till the patient discharged from hospital. Patient will perform 5 sets. In each set, 10 times will be included. Then, instruct the patient to take deep breath through nose for two counts, and keep mouth closed. Inhale for 2 seconds. Now, ask the patient to purse the lips as if the patient was going to gently flicker the flame of candle. Now the patient will breathe out gently while counting for 4 seconds.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: coordinated breathing technique
Description: Put one hand on your abdomen. Make your abdomen push out while you breathe in through your nose. Suck in your abdominal muscles. Breathe out using the pursed-lip technique. You should feel your abdomen go down. Repeat three times and rest for two minutes.
Study: NCT04583254

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy (EBRT) + High-dose rate (HDR) Brachytherapy Experimental
Description: 40 Gy / 15 Fractions EBRT + HDR-Brachytherapy
Study: NCT04813991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg
Description: Ibuprofen 600 mg for breakthrough pain.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OxyCODONE 5 Mg Oral Capsule
Description: OxyCODONE 5 Mg Oral Capsule for breakthrough pain.
Study: NCT04583254

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External beam radiotherapy (EBRT) + High-dose rate (HDR) Brachytherapy Standard of Care
Description: 45 Gy / 25 Fractions EBRT + HDR-Brachytherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent Chemotherapy
Description: Weekly cisplatin 40 mg/m2 for a maximum of 5 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent Chemotherapy
Description: Weekly cisplatin 40 mg/m2 for a maximum of 5 cycles
Study: NCT04697186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine
Description: berberine , amoxicillin and rabeprazole triple therapy group: given for 14 days at a dose of berberine 100 mg 3 tablets TID, amoxicillin 500 mg 2 capsules BID ，rabeprazole 10 mg BID.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: berberine , amoxicillin and rabeprazole triple therapy group: given for 14 days at a dose of berberine 100 mg 3 tablets TID, amoxicillin 500 mg 2 capsules BID ，rabeprazole 10 mg BID.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: berberine , amoxicillin and rabeprazole triple therapy group: given for 14 days at a dose of berberine 100 mg 3 tablets TID, amoxicillin 500 mg 2 capsules BID ，rabeprazole 10 mg BID.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Bismuth-containing Quadruple Therapygroup: given for 14 days at a dose of amoxicillin 500 mg 2 capsules BID ，clarithromycin 500mg BID ,rabeprazole 10 mg BID and bismuth 110 mg 2 capsules BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: Bismuth-containing Quadruple Therapygroup: given for 14 days at a dose of amoxicillin 500 mg 2 capsules BID ，clarithromycin 500mg BID ,rabeprazole 10 mg BID and bismuth 110 mg 2 capsules BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabeprazole
Description: Bismuth-containing Quadruple Therapygroup: given for 14 days at a dose of amoxicillin 500 mg 2 capsules BID ，clarithromycin 500mg BID ,rabeprazole 10 mg BID and bismuth 110 mg 2 capsules BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth
Description: Bismuth-containing Quadruple Therapygroup: given for 14 days at a dose of amoxicillin 500 mg 2 capsules BID ，clarithromycin 500mg BID ,rabeprazole 10 mg BID and bismuth 110 mg 2 capsules BID
Study: NCT05753930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imlifidase
Description: Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.
Study: NCT04855097

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: BVA-100
Description: The BVA-100 is a medical device that calculates human blood volume using the method of tracer dilution. The device utilizes a tracer of human serum albumin tagged with iodine-131 to measure injected intravascularly and a series of timed blood draws. The amount of tracer in each blood draw is used to calculate the unknown blood volume. Data inputs come from the measured characteristics of subject blood samples (hematocrit and tracer concentration) and tracer calibration standards. The package also calculates the subject expected (or ideal) blood volume from physical parameters. Hyper- or hypovolemia, associated red blood cell volumes, and tracer transudation rate are reported, with statistics showing the quality of the results.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: BVA-100
Description: The BVA-100 is a medical device that calculates human blood volume using the method of tracer dilution. The device utilizes a tracer of human serum albumin tagged with iodine-131 to measure injected intravascularly and a series of timed blood draws. The amount of tracer in each blood draw is used to calculate the unknown blood volume. Data inputs come from the measured characteristics of subject blood samples (hematocrit and tracer concentration) and tracer calibration standards. The package also calculates the subject expected (or ideal) blood volume from physical parameters. Hyper- or hypovolemia, associated red blood cell volumes, and tracer transudation rate are reported, with statistics showing the quality of the results.
Study: NCT06034067

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osseodensification osteotomy preparation
Description: The implant site will be prepared by raising a mucoperiosteal flap. Implant osteotomy will be prepared by using osseodensification technique using Versah burs and a dental implant will be placed. The flaps will then be replaced and sutured with 4/0 polyglycolic acid interrupted and mattress sutures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standardized osteotomy preparation
Description: The implant site will be prepared by raising a mucoperiosteal flap. Implant osteotomy will be prepared by using either conventional surgical drills provided by Straumann implant systems and a dental implant will be placed. The flaps will then be replaced and sutured with 4/0 polyglycolic acid interrupted and mattress sutures.
Study: NCT06469866

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low-pressure pneumoperitoneum
Description: low-pressure pneumoperitoneum (LPP) with deep NMB.
Study: NCT05042258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: 12 week dupilumab administration
Study: NCT06469866

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low-pressure pneumoperitoneum
Description: low-pressure pneumoperitoneum (LPP) with deep NMB.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: standard-pressure pneumoperitoneum
Description: standard-pressure pneumoperitoneum (SPP) with moderate NMB.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: standard-pressure pneumoperitoneum
Description: standard-pressure pneumoperitoneum (SPP) with moderate NMB.
Study: NCT04824885

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chlorhydric acid based acid concentrate for bicarbonate hemodialysis (medical device)
Description: usual dialysate (A + D) for 6 months and then switch to A-D dialysate for the next 6 months

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chlorhydric acid based acid concentrate for bicarbonate hemodialysis (medical device)
Description: usual dialysate (A + D) for 6 months and then switch to A-D dialysate for the next 6 months
Study: NCT05741008

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Target range
Description: Compared with conventional radiotherapy, the target dose is unchanged and the CTV2 volume is reduced.
Study: NCT05744453

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Olive Leaf Extract
Description: experimental arm

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cellulose
Description: placebo comparator arm
Study: NCT06229548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYH2053
Description: subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous injection
Study: NCT06223386

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Designed on-line course A with 3-month consultation with the dietitian
Description: Educational materials on weight reduction will be provided at the beginning of the 3-month intervention. Participants can consult with the dietitian via the APP on their mobile phones during the intervention period. These materials will encompass dietary and physical activity guidelines by the government in Taiwan.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Designed on-line course B with 3-month consultation with the dietitian
Description: Educational materials on weight reduction will be provided every weekday for 8 weeks. Participants can consult with the dietitian via the APP on their mobile phones during the 3-month intervention period. These materials will encompass various aspects such as dietary habits, physical activity, and daily routines, all designed to impart online lifestyle education.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Designed on-line course B with 3-month consultation with the dietitians + 3-month daily dietary assessment by the dietitians
Description: Educational materials on weight reduction will be provided every weekday for 8 weeks. Participants can consult with the dietitian via the APP on their mobile phones during the 3-month intervention period. These materials will encompass various aspects such as dietary habits, physical activity, and daily routines, all designed to impart online lifestyle education. In addition, dietitians assess participants' daily diet for 3 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Designed on-line course B with 6-month consultation with the dietitians + 6-month daily dietary assessment by the dietitians
Description: Educational materials on weight reduction will be provided every weekday for 8 weeks. Participants can consult with the dietitian via the APP on their mobile phones during the 6-month intervention period. These materials will encompass various aspects such as dietary habits, physical activity, and daily routines, all designed to impart online lifestyle education. In addition, dietitians assess participants' daily diet for 6 months.
Study: NCT05158088

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Borescope
Description: Endotracheal intubation using borescope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Video laryngoscope
Description: Endotracheal intubation using video laryngoscope
Study: NCT04693416

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intrapersonal Stigma Reduction
Description: Brief intervention for stigma reduction

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interpersonal Stigma Reduction
Description: Brief intervention for support persons of intrapersonal intervention participants.
Study: NCT05213039

Intervention type: OTHER
Intervention: assessments
Description: All of the children with cerebral palsy will be assessed by two different physiotherapist observers. The timed 360° turn test, Expanded and revised Gross Motor Function Classification System (GMFCS-E\&R) for functional motor levels of the subjects, lower extremity muscle tone will be measured with the Modified Ashworth Scale (MASH) at the beginning of the one-time study and recorded. Pediatric Berg Balance Scale, Timed Up and Go Test, Pediatric Functional Reaching test and Modified Four Square Stepping Test, 3m walking back test (3MGYT) will be performed.Evaluations will be made by two separate physiotherapists with at least 5 years of experience in this field. The time it took for individuals to complete activities during the tests with a stopwatch will be recorded.
Study: NCT05223881

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 13^C Spirulina Platensis Gastric Emptying Breath Test (GEBT)
Description: After an overnight (minimum 8 hours) fast, patients are given a standardized test meal, after which they are administered the GEBT. Patients are asked to hold a glass tube in a comfortable position, take a deep breath and pause momentarily, blow gently into the tube for 5 - 10 seconds, slowly withdraw straw from tube while continuing to breath into tube, and immediately close the tube securely with the cap.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 13^C Spirulina Platensis Gastric Emptying Breath Test (GEBT)
Description: After an overnight (minimum 8 hours) fast, patients are given a standardized test meal, after which they are administered the GEBT. Patients are asked to hold a glass tube in a comfortable position, take a deep breath and pause momentarily, blow gently into the tube for 5 - 10 seconds, slowly withdraw straw from tube while continuing to breath into tube, and immediately close the tube securely with the cap.
Study: NCT05108090

Intervention type: PROCEDURE
Group type: OTHER
Intervention: sentinel lymph node biopsy (SLNB)
Description: Preoperative Lymphoscintigraphy: A standard injection of 2 mCi of 99m-Technetium sulfur colloid. Sequential immediate and delayed images will be obtained using SPECT/CT using a gamma probe. Ten-second counts will be done in areas of high activity to identify location of sentinel lymph node (SLN). After removal of the lymph node, a 10-second count will be done of the lymph node ex-vivo followed by 10-second count of the lymph node resection bed to ensure removal of SLN (less than 10% activity of LN).~Surgical resection: Mohs micrographic surgery followed by SLNB. Intraoperative margins around the tumor will be confirmed through frozen section analysis. Patients with planned free flap reconstruction, will undergo SLNB with intraoperative, frozen section analysis. If lymph node is positive, immediate completion neck dissection will occur.
Study: NCT05093543

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical rehabilitation/physiotherapy and psychosocial group sessions
Description: physical rehabilitation/physiotherapy and psychosocial group sessions
Study: NCT05315427

Intervention type: OTHER
Intervention: one music therapy session
Description: Edmonton Symptom Assessment System (ESAS) scale (before and after music therapy session), Numerical pain scale (before and after music therapy session)
Study: NCT06015763

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endoscopy
Description: Endoscopic biopsy
Study: NCT05206994

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Close to Home
Description: Close to Home (C2H), a community mobilization model developed in Boston and adapted for California, is specifically designed to prevent SV by strengthening community social connections and engaging whole communities in dialogue and action to transform social norms. The C2H model guides communities through four phases: 1) Assess, 2) Talk, 3) Build, and 4) Act. C2H mobilizes diverse groups of people residing in a shared geography and linked by social and political ties to engage in joint actions for SV prevention
Study: NCT06176014

Intervention type: PROCEDURE
Group type: OTHER
Intervention: implant placement
Description: 5 implant were placed in intraforaminal area using surgical guide
Study: NCT06467110

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcatheter mitral valve clip delivery system and steerable guide catheter (Shenqi Medical)
Description: The principle of this product is the transcatheter interventional edge-to-edge repair technology (edge-to-edge repair). The core technology is to treat the regurgitation by edge-to-edge suturing the mitral valve. The double holes are set in the mitral valve (A2/P2 zone) or the edges in A1/P1 or A3/P3 zones are apposed and closed to treat regurgitation.